Richter M, Murtaza N, Scharrenberg R, White SH, Johanns O, Walker S, et al
Most symptoms are mild to moderate, transient, and resolve within 4-8 weeks as physiologic tolerance develops
Its given them a reason to say, Oh, MTHFR caused this. No, it didnt
In reputable 503A compounded tirzepatide, yes
The DECLARE, CANVAS and EMPA-REG CV outcomes trials assessing the SGLT2 inhibitors dapagliflozin (Farxiga, AstraZeneca), canagliflozin (Invokana, Janssen) and empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), respectively, all showed CV and renal benefit in adults with type 2 diabetes with established CVD, DeFronzo said
For pilot studies or budget-constrained projects where oral administration isn't a factor, the acetate salt remains a viable and economical choice